Unveiling 5 Analyst Insights On Editas Medicine
Unveiling 5 Analyst Insights On Editas Medicine
揭示editas medicine的5個分析師見解
Throughout the last three months, 5 analysts have evaluated Editas Medicine (NASDAQ:EDIT), offering a diverse set of opinions from bullish to bearish.
在過去的三個月中，有5位分析師對納斯達克：EDIT的Editas Medicine進行了評估，提出了看好到看淡的不同觀點。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
以下表格總結了分析師們最近的評級，揭示了過去30天內情緒的變化並將其與前幾個月進行了比較。
In the assessment of 12-month price targets, analysts unveil insights for Editas Medicine, presenting an average target of $10.0, a high estimate of $15.00, and a low estimate of $7.00. This current average represents a 25.93% decrease from the previous average price target of $13.50.
在12個月的價格目標評估中，分析師揭示了Editas Medicine的見解，給出了一個平均目標價10.0美元，高估值爲15.00美元，低估值爲7.00美元。這個當前的平均值比之前的平均價格目標13.50美元下降了25.93%。
Interpreting Analyst Ratings: A Closer Look
解讀分析師評級：更深入的了解
The analysis of recent analyst actions sheds light...
對最近的分析師行...
登入免費觀看全文
登入/註冊